Sandbox Reserved 425: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 47: | Line 47: | ||
==Quiz Question 1== | ==Quiz Question 1== | ||
Ponatinib is unique in it's ability to bind to the mutated BCR-ABL because of it's preference to shift to the DFG-out conformation. In theory, if a competitive inhibitor was created by nature to prevent Ponatinib from binding to BCR-ABL to further its drug resistance, what specific structural characteristics would the inhibitor need to | Ponatinib is unique in it's ability to bind to the mutated BCR-ABL because of it's preference to shift to the DFG-out conformation. In theory, if a competitive inhibitor was created by nature to prevent Ponatinib from binding to BCR-ABL to further its drug resistance, what specific structural characteristics would the inhibitor need to possess? Consider the unique binding methods of Ponatinib and the <scene name='48/483882/Active_sitezoom/1'>DFG-out</scene> conformation. | ||
a. Small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding. | a. Small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding. | ||
